Trials / Completed
CompletedNCT00556699
A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma
An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics, and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed Following Previous Rituximab Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter Phase Ib study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive, follicular or marginal zone NHL who have received at least one prior rituximab-containing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab | Escalating intravenous repeating dose |
| DRUG | SGN-40 | Escalating intravenous repeating dose |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2007-11-12
- Last updated
- 2014-03-20
Source: ClinicalTrials.gov record NCT00556699. Inclusion in this directory is not an endorsement.